CNS Pharmaceuticals Announces it Has No Exposure to Silicon Valley Bank Issues Mar 13, 2023 7:05am EDT
CNS Pharmaceuticals Continues Momentum in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM with First Patient Enrolled in Switzerland Mar 9, 2023 9:05am EST